Montes Archimedes Acquisition (ROIV)
(Delayed Data from NSDQ)
$10.72 USD
+0.07 (0.66%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $10.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ROIV 10.72 +0.07(0.66%)
Will ROIV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ROIV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ROIV
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
ROIV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Stock Market News for Nov 14, 2023
Immunovant (IMVT) Soars on Upbeat Initial IMVT-1402 Study Data
Roivant Sciences Ltd. (ROIV) Moves 21.6% Higher: Will This Strength Last?
Other News for ROIV
Buy Rating on Roivant Sciences Amid Anticipation of High-Potential Phase 2 Asset Reveal
Tracking Baker Brothers Portfolio - Q1 2024 Update
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), Replimune Group (REPL) and Roivant Sciences (ROIV)
The 'Undercovered' Dozen From June 1-6
Roivant Sciences: Executing On Huge Buyback Program With More To Come